Who are Pneumovax™23's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Investigational 23-valent PPV, PPV Vaccine, Pneumococcal polysaccharide vaccine, Control 23-valent PPV, ProDiax-23 (PPSV23), PPV23 alone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pneumovax23.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Pneumovax™23 — Competitive Intelligence Brief

Pneumovax™23 (Pneumovax™23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polysaccharide vaccine. Area: Immunology.

marketed Polysaccharide vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Pneumovax™23 (Pneumovax™23) — Merck Sharp & Dohme LLC. Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pneumovax™23 TARGET	Pneumovax™23	Merck Sharp & Dohme LLC	marketed	Polysaccharide vaccine
Investigational 23-valent PPV	Investigational 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
PPV Vaccine	PPV Vaccine	Fakultas Kedokteran Universitas Indonesia	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides
Pneumococcal polysaccharide vaccine	Pneumococcal polysaccharide vaccine	Celgene	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
Control 23-valent PPV	Control 23-valent PPV	Sinovac Biotech Co., Ltd	marketed	Pneumococcal polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
ProDiax-23 (PPSV23)	ProDiax-23 (PPSV23)	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)
PPV23 alone	PPV23 alone	Korea University Guro Hospital	marketed	Polysaccharide vaccine	Streptococcus pneumoniae capsular polysaccharides (23 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polysaccharide vaccine class)

Korea University Guro Hospital · 2 drugs in this class
Celgene · 1 drug in this class
Fakultas Kedokteran Universitas Indonesia · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Hualan Biological Engineering, Inc. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class
University of Minnesota · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Walvax Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pneumovax™23 — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumovax23. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab